Monika Sas-Wyżykowska

Monika Sas-Wyżykowska

Auto-generated profile, based on publicly available information

Monika Sas-Wyżykowska

Faculty of Medicine, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AWAnna Wyżykowska
Anna Wyżykowska
MMMonika Maruszak
Monika Maruszak
JGJulia Grygorowicz
Julia Grygorowicz
MNMichał Niedziela
Michał Niedziela
GFGabriela Faria
Gabriela Faria
ABAleksandra Blachucik
Aleksandra Blachucik
Psychological distress, including depression and anxiety, represents a major clinical concern in patients with advanced cancer, particularly in palliative care settings, where it is associated with reduced quality of life, increased symptom severity, and impaired adherence to oncological treatment. The diagnosis of these conditions remains challenging due to the overlap between psychiatric and disease-related somatic symptoms, as well as the complex and multidimensional nature of distress in this population. This review examines key diagnostic challenges and current approaches to pharmacological management of depression and anxiety in advanced cancer, with particular emphasis on palliative care populations. The analysis is based on selected clinical guidelines and relevant clinical studies addressing both diagnostic and therapeutic aspects of care. Available evidence indicates that standard diagnostic criteria may have limited applicability in medically ill patients, requiring careful clinical interpretation and individualized assessment. Pharmacological treatment remains an important component of care, while symptom-oriented strategies and selected adjunctive agents may provide additional clinical benefit, and rapid-acting therapies represent a promising but still evolving area of research. Effective management requires a flexible, patient-centered approach that integrates clinical context, symptom profile, and treatment goals. Further research is needed to improve diagnostic strategies and to develop more effective and rapidly acting therapeutic options in palliative care settings.

5 October 2026 in Aktualności Neurologiczne
Verified
Journal Article
Open access
MNMichał Niedziela
Michał Niedziela
MMMonika Maruszak
Monika Maruszak
AWAnna Wyżykowska
Anna Wyżykowska
JGJulia Grygorowicz
Julia Grygorowicz
GFGabriela Faria
Gabriela Faria
AKAliaksandr Kryshtofik
Aliaksandr Kryshtofik
Multiple sclerosis is a chronic autoimmune disorder characterised by inflammation, demyelination, and progressive neurodegeneration within the central nervous system. In recent years, increasing attention has been directed towards the potential role of the gut microbiota in the pathogenesis of multiple sclerosis. Intestinal microorganisms interact with the immune system and may influence neuroinflammatory processes through the gut–brain axis. Growing evidence suggests that disturbances in gut microbial composition may contribute to the immune dysregulation observed in patients with multiple sclerosis. The aim of this narrative review is to summarise current knowledge regarding alterations in gut microbiota composition in individuals with multiple sclerosis, as well as to discuss the immunological mechanisms linking intestinal microorganisms with disease development. A comprehensive literature search was performed using the PubMed, Scopus, and Web of Science databases. Studies addressing gut microbiota, immune mechanisms, and microbiota-targeted therapeutic strategies in multiple sclerosis were analysed and synthesised. Available evidence indicates that patients with multiple sclerosis often present alterations in gut microbial composition, including reduced abundance of beneficial commensal bacteria and increased representation of pro-inflammatory taxa. These changes may influence immune responses through mechanisms involving T-cell differentiation, cytokine signalling, and microbial metabolite production. Experimental and clinical studies also suggest that microbiota-targeted interventions, such as probiotic supplementation or modulation of microbial metabolites, including short-chain fatty acids, may affect inflammatory pathways involved in multiple sclerosis. Although current clinical evidence remains limited, a growing body of research indicates that modulation of the gut microbiota may represent a promising complementary strategy in the management of multiple sclerosis.

13 July 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
JGJulia Grygorowicz
Julia Grygorowicz
MMMonika Maruszak
Monika Maruszak
AWAnna Wyżykowska
Anna Wyżykowska
GFGabriela Faria
Gabriela Faria
AMAlina Mykhalevych
Alina Mykhalevych
ABAleksandra Blachucik
Aleksandra Blachucik
Background. Irritable bowel syndrome (IBS) is a prevalent disorder of gut-brain interaction (DGBI) affecting 5-20% of children worldwide, with the microbiota-gut-brain axis (MGBA) playing a central pathophysiological role [7, 8, 21]. Aim. This narrative review evaluates MGBA-targeted therapeutic interventions in pediatric IBS. Materials and methods. A systematic search of PubMed/MEDLINE (2021-2025) following PRISMA guidelines identified 31 eligible studies from 45 initially screened articles. Results. Pediatric IBS pathophysiology involves intestinal dysmotility, visceral hypersensitivity, dysbiosis, and altered central processing of visceral signals [14, 15, 26]. The low-FODMAP diet has demonstrated efficacy in adults; however, pediatric evidence remains limited to five randomized trials with inconsistent results [25]. Probiotic supplementation with Lactobacillus rhamnosus GG and Limosilactobacillus reuteri DSM 17938 shows strain-specific efficacy [3, 4]. Cognitive-behavioral therapy and gut-directed hypnotherapy effectively target central signal processing [5, 21]. Pharmacological options, including neuromodulators, remain understudied in pediatric populations, with off-label use predominating [2, 12]. Psychological comorbidities, particularly anxiety and depression, significantly influence treatment response [1, 18]. Conclusions. The MGBA represents the primary therapeutic target in pediatric IBS, supporting multimodal approaches, but limitations in pediatric-specific evidence suggest the need for high-quality randomized controlled trials with standardized outcome measures and adequate long-term follow-up [6, 31].

14 July 2026 in Quality in Sport
Verified
Journal Article
Open access
AKAliaksandr Kryshtofik
Aliaksandr Kryshtofik
JGJulia Grygorowicz
Julia Grygorowicz
GFGabriela Faria
Gabriela Faria
MSMonika Sas-Wyżykowska
Monika Sas-Wyżykowska
AMAlina Mykhalevych
Alina Mykhalevych
ASAkhil Roy Subramoney
Akhil Roy Subramoney
Background: Parkinson’s disease (PD) is the fastest-growing neurological disorder globally. Traditional diagnosis, which relies on motor symptoms, is associated with a 15–24% error rate and occurs after significant loss of dopaminergic neurons. Early biomarker identification is essential for biological redefinition of PD and timely intervention.Objective: To synthesize evidence from the past five years on minimally invasive biomarkers and assess whether multimodal panels offer greater diagnostic precision than single tests.Methods: A systematic review of PubMed and Scopus (January 2021–January 2026) was conducted per PRISMA guidelines, including meta-analyses and original studies on α-synuclein seed amplification assays (SAA), neuronally derived extracellular vesicles (LIEVs), neurofilament light chain (NfL), and advanced imaging (OCT-A, MRI).Results: SAA exhibited 96% sensitivity in GBA1 mutation carriers and 98.6% in hyposmic individuals with dopaminergic deficits, but only 67.5% in LRRK2 carriers. Serum LIEV-associated α-synuclein distinguished prodromal cases with high precision (AUC=0.91). NfL predicted functional decline (OR=2.54) up to five years before diagnosis. Advanced neuroimaging and skin RT-QuIC tests showed diagnostic accuracies from 82% to 100%.Conclusion: PD diagnosis is shifting from clinical observation to biological profiling. Multimodal biomarker panels integrating molecular, microvascular, and imaging data provide the most precise risk stratification, enabling timely, targeted neuroprotective interventions by rehabilitation specialists.

8 October 2026 in Pediatria Polska
Verified
Journal Article
Open access
PDF file
AMAlina Mykhalevych
Alina Mykhalevych
JGJulia Anna Grygorowicz
Julia Anna Grygorowicz
MSMonika Sas-Wyżykowska
Monika Sas-Wyżykowska
AKAliaksandr Kryshtofik
Aliaksandr Kryshtofik
MNMichał Niedziela
Michał Niedziela
GFGabriela Faria
Gabriela Faria
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis, is a growing global health challenge, with approximately 25% of cases diagnosed before the age of 20. These chronic immune- mediated disorders result from complex interactions between genetic predisposition, environmental triggers, gut microbiome alterations, and immune dysregulation. Pediatric IBD presents with more extensive disease than adult-onset cases, with unique manifestations including growth failure and delayed puberty. Diagnosis relies on clinical assessment, fecal calprotectin, and endoscopic evaluation. Contemporary management emphasizes treat-to-target strategies using exclusive enteral nutrition (60–80% remission rates) and biologic therapies for moderate- to-severe disease. Anti-TNF agents remain first-line biologics, while ustekinumab has recently received Food and Drug Administration and European Medicines Agency approvals for pediatric CD based on the UNITI Jr trial, and emerging data on JAK inhibitors further expand the therapeutic landscape. This review provides a comprehensive overview of disease subtypes, pathophysiology, diagnostics, and evidence-based treatment strategies.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GFGabriela Faria
Gabriela Faria
AWAnna Wyżykowska
Anna Wyżykowska
MMMonika Maruszak
Monika Maruszak
JGJulia Grygorowicz
Julia Grygorowicz
MNMichał Niedziela
Michał Niedziela
ABAleksandra Blachucik
Aleksandra Blachucik
Dexmedetomidine is a highly selective alfa2-adrenergic agonist increasingly used in pediatric anesthesia and intensive care because of its unique sedative profile and minimal respiratory depressive effects. This narrative summarizes current evidence regarding the pharmacology, pharmacokinetics, clinical efficacy, safety profile and emerging applications of dexmedetomidine in pediatric patients. Current literature supports the use of dexmedetomidine in multiple clinical settings, including procedural sedation, perioperative management, and pediatric intensive care. The drug has demonstrated efficacy in reducing opioid requirements, preventing emergence agitation and delirium, and providing effective sedation while preserving spontaneous respiration. However, its use remains associated with dose-dependent cardiovascular adverse effects, particularly bradycardia and hypotension, requiring individualized dosing and careful monitoring, especially in neonates and infants due to age-related pharmacokinetic variability. Emerging evidence suggests potential neuroprotective and organ-protective properties, although robust pediatric clinical data remains limited. Novel applications and alternative administration routes continue to expand the potential role of dexmedetomidine in pediatric practice. Overall, dexmedetomidine represents a versatile and valuable sedative agent in pediatric medicine, though further high-quality studies are needed to optimize dosing strategies and better define long-term safety outcomes.